Common mutation is culprit in acute leukemia relapse.

Harvard stem cell scientists have identified a mutation in human cases of acute lymphoblastic leukemia that likely drives relapse.
This could provide us a lot of improvements for this disease that affects both children and adults and in many cases is often fatal.
After several analyzes have found that in a single cell can accumulate several mutations actually aggressive and capable of surviving at treatments.
These experiments have been performed in zebrafish, discovering in them many mutant leukemia cells resistant to treatments such as chemotherapy. These cells have an important duty motor in via Akt, which allowed them greater growth and spread.
A co-treatment with inhibitors of the Akt pathway and typical front-line cancer therapy would be very effective in these cells. 
(http://www.sciencedaily.com/releases/2014/03/140306130419.htm)